Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

M Charokopou,H Vioix,L.A Eddowes,K Tolley,B Verheggen,M Griffiths,Z Gabriel,D Franks

doi:10.1016/j.jval.2014.08.709

Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

M Charokopou, H Vioix + Show 6 more

Open Access

https://doi.org/10.1016/j.jval.2014.08.709

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Oct 26, 2014
Citations: 1	License type: elsevier-specific: oa user license

Affiliation: Pharmerit (Netherlands), AstraZeneca (United Kingdom), Costello Medical Consulting (United Kingdom), Buxton Hospital

#Uk Health Care Perspective #Diabetes Mellitus + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

Full Text